Gene therapy trial markedly cuts bleeding risk in haemophilia B patients

Single injection of FLT180 removes need for people to inject weekly with clotting factors, study finds

A new gene therapy has dramatically cut the risk of bleeding in people with the rare condition haemophilia B, experts have said.

Researchers found that a single injection of the gene therapy, called FLT180a, removed the need for people to inject themselves weekly with clotting factors. The study was led by experts from University College London (UCL), the Royal Free hospital in London and the biotechnology company Freeline Therapeutics.